Home  >  Investors  >  Investor Resources  >  Financial Tear Sheet

Financial Tear Sheet

Corporate Profile

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a worldleading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2017 were $22.4 billion. For more information, visit www.tevapharm.com.

Primary IR Contact
Investor Relations
Phone: (215) 591-3034
E-mail: ir@tevapharm.com

SEC Filings

Date Filing Type Filing Description Download / View

Financial Reports


Corporate Officers

Kåre Schultz
President and CEO

Iris Beck-Codner
Executive Vice President, Global Brand & Communications

Richard Daniell
Executive Vice President, European Commercial

Sven Dethlefs
Executive Vice President, Global Marketing & Portfolio

Dr. Hafrun Fridriksdottir
Executive Vice President, Global R&D

Michael (Mike) McClellan
Executive Vice President, Chief Financial Officer

Gianfranco Nazzi
Executive Vice President, Growth Markets Commercial

Dr. Carlo de Notaristefani
Executive Vice President, Global Operations

Brendan O'Grady
Executive Vice President, North America Commercial

Mark Sabag
Group Executive Vice President, Human Resources

David M. Stark
Group Executive Vice President, Chief Legal Officer

Nir Baron
Executive Vice President, Chief Internal Auditor